QURE Overview
Upcoming Projects (QURE)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (QURE)
-
Examining uniQure's AMT-130 and PTC Therapeutics' PTC518: Data on Slowing Huntington's Disease Progression
Tickers: QURE, PTCT
Executed On: Jul 12, 2024 at 11:15 AM EDT -
Discussing the potential of uniQure's gene therapy AMT-130 and PTC Therapeutics candidate PTC518 in Huntington's Disease.
Tickers: QURE, PTCT
Executed On: Jul 18, 2023 at 12:00 PM EDT -
Exploring the current treatment landscape for Hemophilia A & B, including CSL Behring's Hemgenix (etranacogene dezaparvovec-drlb) and Biomarin's potential gene therapy ROCTAVIAN (valoctocogene roxaparvovec)
Tickers: BMRN, CSLLY, QURE
Executed On: Apr 25, 2023 at 09:00 AM EDT -
A Second Look: Discussing the standard of care for Hemophilia B and the potential of etranacogene dezaparvovec in light of it's recent BLA priority review by the FDA
Ticker: QURE
Executed On: Jun 02, 2022 at 06:10 PM EDT -
Discussing the the standard of care for Hemophilia B and the potential of etranacogene dezaparvovec in light of it's recent BLA priority review by the FDA
Ticker: QURE
Executed On: May 27, 2022 at 12:00 PM EDT
Upcoming & Overdue Catalysts (QURE)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (QURE)
-
uniQure (QURE) Announces FDA Removes Clinical Hold on Hemophilia B Gene Therapy Program
Ticker: QURE
Occurred on: Apr 26, 2021 -
EMA Designates UniQure's (QURE) AMT-060 for PRIME Status in Hemophilia B
Ticker: QURE
Occurred on: Apr 25, 2017 -
Updated trial data show uniQure's gene therapy AMT-060 induces sustained Factor IX activity in patients with hemophilia B
Ticker: QURE
Occurred on: Jul 27, 2016 -
Phase 1/2 clinical trial preliminary data of AMT-060 for hemophilia B due January 2016
Ticker: QURE
Occurred on: Jan 07, 2016
Strategic Initiatives (QURE)
-
uniQure (QURE) Announces Strategic Plan to Reduce Costs and Drive Shareholder Value
Ticker: QURE
Announcement Date: Nov 15, 2016
